Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Preclinical data showed GB3226's superior efficacy to both FLT3 and menin inhibitors in animal models, as well as ... trial of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic ...

Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a ...

Researchers have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa.

A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with ...

Telomir Pharmaceuticals (TELO) announced on Wednesday preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate ca ...

of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto ...

Merck (NYSE:MRK) and Pfizer (NYSE:PFE) finish as the year's top gainers on the Dow Jones Industrial Average, as 14 of the 30... By Tamara Mathias (Reuters) - Merck and Co (N:MRK) said on Friday it ...

The median PFS for pembrolizumab - the world's most popular ... industry with its high performance artificial intelligence (AI) models developed at a much lower cost than its peers.